Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …

Blockade of epidermal growth factor receptor (EGFR) by EGFR tyrosine kinase inhibitors is
insufficient for effective antitumor activity because of independently activated survival …

Background Sorafenib is the only systemic agent to show statistically significant overall
survival (OS) benefits in advanced HCC. Erlotinib is a direct and reversible EGFR tyrosine …

Introduction: Most epidermal growth factor receptor (EGFR) mutant non-small cell lung
cancers (NSCLCs) are sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib …

Hepatocarcinogenesis is a complex multistep process in which many different molecular
pathways have been implicated. Hepatocellular carcinoma (HCC) is refractory to …

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK)
receptor that is frequently expressed in many epithelial tumors. The signaling pathways of …

BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …

The epidermal growth factor receptor (EGFR) is a target of new therapies in most
nonhematologic cancers. EGFR blockade alone may not be sufficient for the control of …

Unlike most solid tumors, the incidence and mortality of hepatocellular carcinoma (HCC)
have increased in the United States and Europe in the past decade. Most patients are …